Skip to main navigation Skip to search Skip to main content

Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study

  • Department of Neurology, 8934 AD Leeuwarden, Netherlands
  • Departments of Clinical Chemistry, Amsterdam, Netherlands
  • Departments of Pathology, Amsterdam, Netherlands
  • Departments of Neurology, Amsterdam, Netherlands

Research output: Contribution to journalArticleAcademicpeer-review

12 Downloads (Pure)

Abstract

To investigate amyloid-β (Aβ) in frontotemporal dementia (FTD), cerebrospinal fluid (CSF) Aβ38, Aβ40, and Aβ42 in frontotemporal lobar degeneration (FTLD; N = 18 genetically and/or pathologically confirmed and N = 8 FTD with concomitant amyotrophic lateral sclerosis) were compared with Alzheimer's disease (AD; pathological or Pittsburgh-compound-B Positron-emission-tomography (PIB-PET) positive; N = 25) and controls (N = 24). For all the Aβ subtypes, group difference was seen and post-hoc analysis revealed lower levels in FTLD compared to controls (p≤0.05). Aβ42/40 ratio showed no difference between FTLD and controls; however, a difference was seen between AD versus FTLD (p < 0.01). This is an intriguing finding, suggesting a possible role of Aβ in FTLD pathogenesis.
Original languageEnglish
Pages (from-to)15-20
JournalJournal of Alzheimer's Disease
Volume71
Issue number1
Early online date22 Jul 2019
DOIs
Publication statusPublished - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alzheimer's disease
  • amyloid
  • frontotemporal dementia
  • frontotemporal lobar degeneration

Fingerprint

Dive into the research topics of 'Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study'. Together they form a unique fingerprint.

Cite this